Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synergistic compound drug for tumor treatment

A drug and compound technology, applied in the fields of medicine and biology, can solve the problems of high drug resistance, unsatisfactory curative effect, and no tumor yet, and achieve the effect of reducing dosage, obvious effect and enhancing ability.

Inactive Publication Date: 2017-08-08
FUDAN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In current clinical practice, surgery, radiation, and drugs are often used to treat tumors, among which drug therapy is still an important means of tumor treatment; because the single drug of chemotherapy makes the human body more likely to develop drug resistance to specific drugs, the curative effect is not ideal Therefore, in order to achieve a better therapeutic effect, multiple anticancer drugs are often used for combined chemotherapy. So far, there has been no report on the synergistic compound drug composed of ceramide and sorafenib for the treatment of tumors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergistic compound drug for tumor treatment
  • Synergistic compound drug for tumor treatment
  • Synergistic compound drug for tumor treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Effect of Sorafenib and Ceramide on the Survival Rate of Bel7402

[0028] After Bel7402 cells were grown to the logarithmic growth phase, 5×10 3 The concentration of cells / ml was transferred to the cell culture plate for culture. After the cells adhered to the wall, the fresh medium was replaced, and different concentrations of sorafenib, ceramide, or the combination of the two were given. Continuous culture was carried out for 48 hours, and 10 μl of MTT was added for reaction. solution, and incubated in the dark at 37°C for 4 hours, after MTT fully reacted with intracellular succinate dehydrogenase to form formazan, add 100 μl dimethyl sulfoxide (DMSO), after dissolution, measure the O.D value of each group at a wavelength of 590nm for comparison The O.D. of the group was 100% for cell viability percentage conversion, and statistical analysis was carried out with graphpad. The results showed that Sorafenib had a dose-dependent increase in the killing effect ...

Embodiment 2

[0032] Example 2 Observation of cell morphology changes after ceramide combined with sorafenib under an optical microscope

[0033] Cells in logarithmic phase were divided into 5×10 3 The density per well is planted in a 6-well plate, and the cells are treated with a certain drug. After that, the changes in cell morphology are observed under an optical microscope. Figure 4 It shows that compared with the normal group and the single-administration group, the combined administration causes the cells to shrink and the number is significantly reduced.

Embodiment 3

[0034] Example 3: Flow cytometry detection of ceramide combined with sorafenib can enhance the apoptosis of tumor cells

[0035] Cells in logarithmic phase were divided into 5×10 3 The density per well is planted in a 6-well plate, and the drug acts for a certain period of time. Collect the cells, wash them twice with pre-cooled phosphate buffered saline, discard the PBS, add 500 μl of buffer to resuspend the cells, add 5 μl of Annexin V and 5 μl of PI, Subsequently, flow cytometry was used to detect the positive ratio of AnnexinⅤ, and the results showed that ceramide combined with sorafenib could enhance the apoptosis of tumor cells (such as Figure 5 shown)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicine, and relates to anti-tumor synergistic drugs, in particular to a synergistic compound drug for tumor treatment composed of one or more ceramides and sorafenib. The compound drug has no obvious cytotoxicity itself, but the tumor cell killing effect can be enhanced remarkably after combined use, and the tumor cell killing effect of sorafenib can be further enhanced by improving the poptotic effect; meanwhile, the dosage of the drug can be reduced, the treatment effect can be improved, and toxic and side effects on the human body can be reduced. The invention further provides a method for using the synergistic compound drug and a pharmaceutical composition thereof, for example, combined administration or sequential usage is adopted to treat liver cancer, kidney cancer, non-small cell lung cancer or thyroid cancer, so as to enhance the tumor killing effect of the drug.

Description

technical field [0001] The invention belongs to the technical fields of biology and medicine. The invention relates to anti-tumor synergistic drugs, in particular to a synergistic compound drug for treating tumors composed of one or more ceramides and sorafenib. Background technique [0002] It is well known in the industry that liver cancer is one of the most common malignant tumors in the world, and its morbidity and mortality are increasing year by year, seriously threatening human health. According to data, due to the presence of serious cancer-causing risk factors such as hepatitis B virus (HBV) infection in China, the morbidity and mortality of liver cancer are particularly severe. Liver cancer can be divided into primary and secondary two categories. Primary liver cancer originates from the epithelial or mesenchymal tissue of the liver, and is a malignant tumor with high incidence and great harm in my country; secondary or metastatic liver cancer refers to the invas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/44A61K31/164A61P35/00
CPCA61K31/44A61K31/164A61K2300/00
Inventor 叶丽姜珊珊王乾冯美卿
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com